Bronchial carcinoma is the most common cause of death from malignant disease in the UK, resulting in more than 30 000 deaths per year 1, 2 . Over 90% of those diagnosed with lung cancer will die from their disease, since presentation is usually at an advanced stage 3 . The distinction between small-cell and non-small-cell carcinomas has important implications for both treatment and prognosis 1, 4 . Small-cell tumours advance rapidly with very early metastatic spread, so chemotherapy is the treatment of choice. Non-small-cell carcinomasÐsquamous cell, undifferentiated and adeno-carcinomasÐaccounting for 75% of lung cancers, divide more slowly and metastasize later 4 . Complete surgical resection is the only curative treatment, with outcome dependent on tumour stage. 5-year survival of patients undergoing resection of stage I tumours is as high as 70%; without surgery, it is a mere 12% 5 . Unfortunately, the onset of symptoms is usually too late in the disease course for de®nitive intervention. If lesions were detected earlier, at an operable stage, patient survival would improve. In this paper we examine the role of screening for non-small-cell lung cancer and consider the prospect of a future screening programme.
The great majority of bronchial malignancies are attributable to a single cause, cigarette smoking, and their incidence rises rapidly between the ages of 40 and 80 years 6 . This delineates a high-risk population who could be targeted with screening. Non-small-cell tumours are believed to take between 8 and 15 years to produce symptoms, so the duration of subclinical disease is long 7 . Detection of presymptomatic lesions also increases the number of patients with early localized disease, in which surgical intervention has been shown to improve outcome 5 . One might therefore expect early detection and treatment to be bene®cial, but several trials in the 1970s showed no improvement in mortality with screening 8 . These negative results have been attributed to¯aws in design, execution and analysis. Biases affecting the trials and their in¯uence upon the results have been discussed previously at length 3,8±10 . However, today the tide of opinion has changed:`absence of evidence is not evidence of absence' of an effect 11 . It is widely accepted that these studies do not provide suf®cient evidence against screening in principle, and the proposition is back under the spotlight 12 .
The search for a suitable screening tool continues. Such a test should have high sensitivity, speci®city and positive predictive value, carry a low cost and little risk, be simple to administer and be acceptable to those screened. New techniques are emerging, but the three modalities that have received most attention are plain chest radiography, sputum cytology and biomarkers, and helical computed tomography.
PLAIN CHEST RADIOGRAPHY
The chest X-ray possesses many of the qualities required for a screening test, being widely available and inexpensive, with low radiation exposure and high patient acceptability. However, the accuracy of this technique in the detection of lung cancer in a symptom-free population has been questioned. A single plain ®lm may be inadequate because of projection (obscuring pulmonary nodules, introducing artifacts) and suboptimal technique (insuf®cient exposure, poor positioning). On a posteroanterior ®lm, approximately 26% of lung volume may be concealed by the thoracic spine, mediastinum, heart and diaphragm 13 . In addition, the contrast capability of chest X-rays is too poor to detect lowdensity tumours, in particular, well-differentiated adenocarcinomas 14 . These inherent weaknesses greatly diminish diagnostic power, and inter-observer variability between radiologists is a limitation.
In some countries, notably Japan and across eastern Europe, lung cancer screening with chest X-rays has been in place for decades, adapted primarily from tuberculosis screening, but without scienti®c evidence 15, 16 . Four large randomized controlled trials have been conducted to assess the use of regular chest X-ray examinations. Three US studies (Mayo, Memorial Sloan±Kettering and Johns Hopkins) looked at more than 30 000 male smokers aged 45 or over, divided into experimental and control groups. Despite improvements in stage, resectability and long-term survival, no bene®t was found in terms of mortality, the primary outcome 3 . The other trial, conducted in the former Czechoslovakia, had similarly disappointing results. This consistency formed the basis of the American Cancer Society's decision in 1980 to withdraw support for lung cancer screening. Debate over the ability of these ®ndings to justify not screening has raged ever since 9 .
All these trials were weakened by contamination; as a frequently used investigation in clinical practice, chest X-rays were taken in many of the control group outside of the screening protocol. The Mayo Lung Project, the only large randomized trial in which the control group received no additional routine screening, lacked suf®cient power to detect a 20% decrease in mortality, which could mean many thousands of lives saved per year 3 .
The sensitivity of chest X-rays is less than 50%, and is highly dependent upon the size and location of the tumour. A recent study found an overall sensitivity of 23%, detecting 29% of peripheral malignancies but none of the 30% obscured by anatomical structures 14 . With such a low sensitivity and point prevalence, a negative result is almost meaningless 3 . Speci®city has been calculated at around 90%. In the US trials, false-positive ®lms were found in 10% of participants, so a large number underwent unnecessary invasive investigations, at physical, emotional and economic costs 3, 8 . This is re¯ected in estimates of positive predictive value between 1% and 23%: the great majority of those with a suspicious chest X-ray do not have lung cancer 8 .
The Prostate, Lung, Colorectal and Ovary (PLCO) Screening Trial is a powerful multi-centre randomized controlled trial in progress in the US 3 . It is comparing annual chest X-ray surveillance with standard care in both men and women aged 60±74. Results are expected within this decade but by then the whole picture may have changed considerably. Case±control studies in Japan have suggested that, whilst regular chest radiographs can reduce lung cancer mortality, a more effective screening tool is required to achieve any substantial bene®t 15 . Chest X-rays are unlikely to feature in any future national programme.
SPUTUM CYTOLOGY AND BIOMARKERS
The collection and cytological examination of sputum is simple, acceptable, non-invasive and cheap with the advantage of detecting centrally placed tumours that may be missed by radiological methods. Disappointingly, in clinical trials cytology proved even less effective than chest X-ray, mainly because of low sensitivity on initial screening and poor subsequent ®nding of malignancy on follow-up 17 . The detection rate was particularly low for non-squamouscell tumours, and in its present form sputum cytology does not seem an effective screening test 3 .
Lately, the advent of molecular biomarkers has provoked renewed interest in sputum collection. These agents could be used either to identify tumours at a very early stage, before radiological detection is possible, or to de®ne high-risk groups that are at increased risk of malignancy and merit more frequent screening. At present, none has been widely studied in the clinical setting; research is needed to assess the sensitivity and speci®city of individual protein and DNA markers to establish effective diagnostic platforms 18 . Their future application is uncertain; probably they will have a role in early detection, monitoring and risk assessment for lung cancer in conjunction with radiological techniques.
COMPUTED TOMOGRAPHY
Computed tomography (CT) is more sensitive than plain chest X-ray for detecting pulmonary nodules. Helical (spiral) CT involves continuous acquisition of volumetric data during a single breath-hold, allowing retrospective reconstruction at any point; it is a rapid, versatile and accurate imaging technique, with the ability to detect small solitary nodules 19 . There is an impressive difference between the size of peripheral tumours found on screening by chest X-ray (averaging 30 mm) and those detected only on helical CT (mean 12 mm) 20 . In addition, the false-positive detection rate has been found to be a quarter that of a plain radiograph 21 . According to one recommendation, helical CT`should be used routinely for thoracic imaging' in patients assessed for lung cancer 19 .
A study from Matsumoto, Japan, of mass screening with helical CT identi®ed almost ten times as many cancers as previous chest X-rays; many of the lesions were too small to have been found by conventional radiography 22 . Both sensitivity and speci®city were calculated to be 95%. Nevertheless, despite leading to early detection and accurate diagnosis, it had a weak positive predictive value and was criticized for the number of unnecessary, extensive and often invasive investigations it engendered 23 . In another study, sensitivities of 95% and 91% were found for lesions greater than and less than 10 mm, respectively, although speci®city was less satisfactory 24 .
The Early Lung Cancer Action Project (ELCAP) in New York is currently evaluating annual screening of high-risk individuals with low-dose helical CT 10 . Initial results suggest that it outperforms chest X-ray in detecting small non-calci®ed lesions, allowing earlier surgical intervention. Although low-dose helical CT generates more false positives, the ELCAP protocol for dealing with suspicious lesions has limited the use of invasive procedures. In addition, the correlation of tumour size and long-term survival from this study will provide a knowledge base against which future screening tests can be compared.
CT had been previously disregarded because of low acceptability and availability and its expense 20 . The initial imaging used in ELCAP takes less than 20 seconds to complete and does not require use of intravenous contrast 10 . A minimally invasive test makes the process both less expensive and more acceptable to those screened: compliance is a prerequisite of any screening programme.
Cost±bene®t analysis of CT has so far received little attention. Preliminary data from Japan suggest that, despite being four times more effective in net person-years saved, CT was almost 1.5 times worse than plain chest X-ray in terms of cost-effectiveness 25 . According to one estimate, annual CT screening of adult smokers in the US would cost in excess of $12 billion, placing enormous demands on radiology department resources 26 . Helical CT images also require more specialist and lengthy interpretation than chest X-rays with greater scope for inter-observer error and falsepositive or false-negative results. Computer-aided diagnosis (CAD) technology is evolving rapidly, becoming highly effective in detecting small pulmonary nodules and in predicting their probability of malignancy 27 . In population screening programmes, CAD could greatly reduce radiologist time-burden, increase positive predictive values and thus improve ef®ciency and cost-effectiveness 20 .
The risk±bene®t ratio of CT as a screening test is of considerable importance since the lesion screened is exposed to a substantial amount of radiation. Conventional CT was reported to have an effective dose between 3.6 and 4.6 mSv; low-dose helical scanners deliver around one-sixth of this dose, which is nevertheless ten times more than plain chest X-ray 20, 28, 29 . The use of`ultra-low-dose' CT, delivering an estimated 0.09±0.15 mSv without evident reduction in lesion detectability, could constitute a considerable breakthrough 30, 31 . We have previously predicted that this would lead to an excess mortality between 1 in 130 000 and 1 in 220 000; and, in view of the underlying risk of a fatal cancer in a targeted population, this low level of exposure would seem to represent an acceptable hazard 31 . In terms of psychological harm, publicity about cancer screening has been shown not to increase worry or subjective risk and may even be reassuring 32 . When CT was used in a population suspected of having cancer the process itself did not seem to cause distress, only uncertainty over the outcome 33 . The use of CT as a screening tool is therefore unlikely to generate much emotional morbidity.
The evolution of CT in lung cancer screening will be directed at reducing radiation exposure, scanning time, costs and image interpretation. As technological improvements maximize its potential, this modality is likely to become a key feature of any future programme.`Virtual bronchoscopy', whereby sequential sections are reconstructed into a three-dimensional image, akin to that under consideration in colorectal screening, has also been considered. Many radiologists judge this technique to be of little added value at present in the routine detection of small lesions, although it may prove useful in selected patients 34 .
The role of positron emission tomography (PET) in lung cancer management has mainly focused on follow-up after chemotherapy and detection of tumour recurrences. A recent study suggested that PET was more accurate than CT in distinguishing recurrent tumour from ®brotic scar 35 . The application of PET alone or in conjunction with CT in primary population screening requires further investigation. Magnetic resonance techniques with enhancement may be an alternative but are not yet clinical options.
CONCLUSIONS: A FUTURE SCREENING PROGRAMME?
Despite being extremely common, occurring in a well-de®ned population and curable only if detected at an early stage, lung cancer is not routinely screened for at a population level in the UK or across most of the developed world. The role of screening has received renewed interest over the past decade with the advent of new techologies but several questions remain unanswered. Population screening should be aimed at high-risk groups determined by established risk factors such as age, sex, smoking status and extent of cigarette exposure 36 . The ELCAP study is following current and ex-smokers over the age of 60 with at least 10 pack-years, but the optimum age at which to start testing has not been established 10 . The issue of false positives is of considerable importance, necessitating an agreed policy for further diagnostic investigations. Such a protocol may involve high-resolution CT with accurate sizing, follow-up and then biopsy of suspicious lesions, in order to limit unnecessary invasive procedures and avoid resection of benign lesions. A thorough statistical and local economic evaluation would also be required before implementation could be considered. At present, low-dose helical CT is undoubtedly the investigation of choice. Results from the 10-year follow-up of participants enrolled in current trials, including positive predictive values, the effects on mortality and the advancement of CAD, are eagerly awaited.
Lung cancer will remain an important health issue, producing an enormous burden of disease, as long as the worldwide epidemic of tobacco consumption continues. Although primary prevention must be central to any drive to reduce mortality in the community, it does not appear to be suf®cient. Even if smoking were to cease, there would be a long delay before substantial reductions in mortality became apparent. Successful screening would ®ll this void by offering a lowering of mortality within a short period. A multidisciplinary strategy comprising anti-smoking promotion (health education, raised taxes, legislation against advertising) and early detection may prove the best form of attack 37 . Despite its potential, there seems little prospect of such a UK national screening programme in the foreseeable future. Whilst improved imaging capabilities, a fall in unitcost and greater expectations in healthcare provision may lead to its limited introduction at some stage, the resources J a n u a r y 2 0 0 1 required are far beyond the scope of an overloaded National Health Service. It would entail a large expansion of workload for radiologists and thoracic surgeons, require modernization of existing equipment and represent a substantial long-term investment. On the other hand, in the private health insurance markets, particularly in the US and Japan, where supply meets demand, CT has already been introduced for the screening of high-risk groups 20 .
